67Cu-SARTATE

67Cu-SARTATE is a copper-based radiopharmaceutical designed for targeted cancer therapy, particularly in tumors expressing somatostatin receptor subtype 2 (SSTR2). It consists of the peptide octreotate linked via Clarity Pharmaceuticals' proprietary SAR Technology to the radioisotope copper-67. The drug acts as a peptide receptor radionuclide therapy (PRRT), delivering beta radiation directly to SSTR2-expressing tumor cells, thereby minimizing damage to healthy tissue. It is being developed primarily for high-risk neuroblastoma and meningioma, with ongoing clinical trials in pediatric neuroblastoma and completed early-phase studies in meningioma. Both 64Cu-SARTATE (diagnostic) and 67Cu-SARTATE (therapeutic) have received FDA Orphan Drug Designation and Rare Pediatric Disease Designation for neuroblastoma. The developer is Clarity Pharmaceuticals, with NorthStar Medical Radioisotopes supplying the therapeutic isotope copper-67[1][2][3][5][6].

Brand names

SARTATE

Other names

sartate